1. IMS Health. Shaping the Biosimilars Opportunity: A Global Perspective on the Evolving Biosimilars Landscape.
http://www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars_Whitepaper.pdf
(IMS Health, London, 2011; accessed January 17, 2014).
2. Biologics Price Competition and Innovation Act of 2009.
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf
(accessed 21 October 2013).
3. US Food and Drug Administration. Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (FDA; Rockville, MD, 2012).
4. Government Accountability Office. Food and Drug Administration Response to Heparin Contamination Helped Protect Public Health; Controls That Were Needed for Working with External Entities Were Recently Added (GAO; Washington, DC, 2010).
5. Olson, K. Alliance for Safe Biologic Medicine—Prescriber Survey.
http://safebiologics.org/resources/wp-content/uploads/2012/09/ASBM-Survey-2.pdf
(ISR, 2012; accessed 21 October 2013).